Clinical efficacy and predictors of effectiveness to anti-TSLP antibody (tezepelumab) in patients with asthma

Not Applicable

Recruiting

• Conditions: Asthma, Cough predominant asthma

• Registration Number: JPRN-UMIN000050222
• Lead Sponsor: agoya City University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-02-03
• Last Update Posted: 17 October 2023
• Study Completion: 2029-02-02

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with other obvious respiratory complications such as lung cancer, interstitial lung disease, etc. 2) Pregnant or lactating patients. 3) Patients who are judged to be inappropriate as subjects by the principal investigator.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To identify predictors of effectiveness at 6 and 12 months after the initiation of tezepelumab.

Secondary Outcome Measures

Name	Time	Method
1) To identify predictors of effectiveness to cough by classifying patients with asthma into "antitussive group" and "non-tussive group" at 6 and 12 months after the initiation of tezepelumab. 2) To evaluate the effect of tezepelumab on capsaicin cough sensitivity at 6 and 12 months after the initiation of treatment. 3) To evaluate the effect of tezepelumab on functional dyspepsia symptoms, gastroesophageal reflux symptoms, and abnormal laryngeal sensation symptoms at 6 and 12 months after the initiation of treatment. 4) To evaluate the effect of tezepelumab at 6 and 12 months after the initiation of treatment, based on the inflammation phenotypes using baseline induced sputum fractions and peripheral blood eosinophil/neutrophil counts.